Levamisole, the story and the lessons.
The history of the use of levamisole in man is summarized, from its start as an anthelmintic in the early sixties, through its world-wide recognition as an immunotropic agent especially in the seventies and early eighties, and its return to clinical prominence in 1989-90 as an effective adjuvant treatment for operable colon cancer. The knowledge accumulated from experimental tumour models and from clinical use in various types of cancer, supplemented with the recent evidence obtained from large-scale controlled trials in resectable colon cancer is reviewed. It is speculated that we may not have seen the end of levamisole story yet; also, the role of serendipidity in drug research is emphasized.
Amery
W K
WK
Janssen Research Foundation, Beerse, Belgium.
Bruynseels
J P
JP
D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy; D006801:Humans; D007978:Levamisole / Q000276:immunology / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*
D007978:Levamisole